Irritable Bowel Syndrome Trial, Recruiting (NCT05740319)

Irritable Bowel Syndrome Trial, Recruiting NCT05740319 Sponsor: Shanghai Zhongshan Hospital Condition: Irritable Bowel Syndrome

Printed from Voxsanity (voxsanity.com.au) — NCT05740319 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Irritable Bowel Syndrome

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with Irritable Bowel Syndrome (IBS) and are between 18 and 70 years old
You have already tried at least 3 standard treatments for IBS without success
You do not have warning signs such as unexplained weight loss or blood in your stool

Who may not be able to join:

You are pregnant, trying to become pregnant, or currently breastfeeding
You have a mental health condition or would have difficulty attending appointments and following the treatment plan
You have a weakened immune system or are taking medication that affects your immune system
You have taken probiotics in the last 3 months or antibiotics in the last month before joining the study
You have had surgery on your abdomen, unless it was an appendix removal, gallbladder removal, caesarean section, or hysterectomy
You have diabetes, high blood pressure, a thyroid condition, or another long-term illness that is not well controlled
You have a serious condition affecting your heart, brain, kidneys, or lungs, or you currently have cancer

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ling Dong, Fudan University

Phone: (86)13817923359

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05740319

Sponsor: Shanghai Zhongshan Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Irritable Bowel Syndrome

Trial contact: (86)13817923359

More information: https://clinicaltrials.gov/study/NCT05740319

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with Irritable Bowel Syndrome (IBS) and are between 18 and 70 years old
You have already tried at least 3 standard treatments for IBS without success
You do not have warning signs such as unexplained weight loss or blood in your stool

Who may not be able to join:

You are pregnant, trying to become pregnant, or currently breastfeeding
You have a mental health condition or would have difficulty attending appointments and following the treatment plan
You have a weakened immune system or are taking medication that affects your immune system
You have taken probiotics in the last 3 months or antibiotics in the last month before joining the study
You have had surgery on your abdomen, unless it was an appendix removal, gallbladder removal, caesarean section, or hysterectomy
You have diabetes, high blood pressure, a thyroid condition, or another long-term illness that is not well controlled
You have a serious condition affecting your heart, brain, kidneys, or lungs, or you currently have cancer

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Shanghai Zhongshan Hospital

Registry

ClinicalTrials.gov

Start date

10 June 2023

Est. completion

31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from baseline IBS symptom severity scale (IBS-SSS) score at 9 weeks; Response rate at 9 weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov